2^nd International Conference and Expo on Biopharmaceutics and Biologic Drugs September 14-16, 2016 San Antonio, USA

I have completed my PhD at the age of 33 years from the university of Birmingham, UK, in 1984. I was the dean of the college of applied science, University of Samarra, Iraq; before that I was the dean of the college of education, University of Tikret, Iraq. I have published more than 30 papers in reputed journals inside and outside Iraq.

This work includes the synthesis of some new octahydro 2-((4R,4aR,5aS,6S)-1,3-dioxo-3,3a,4,4a,5,5a,6,6a-o-4,6-ethenocyclopropa[Æ’]isoindol-2(1H)-yl)-N-( substituted phenyl) acetamides (3-11) by reaction of (4R,4aR,5aS,6S)-4,4a,5,5a,6,6a-hexahydro-4,6- ethenocyclopropa[Æ’] isoindole-1,3(2H,3aH)-dione (1) with 2-chloro-N-(substituted phenyl) acetamides (2) in the presence of potassium carbonate in refluxing acetonitrile as a solvent. These compounds have been identified by using spectroscopic methods including IR,1H-NMR, 13C-NMR and elemental analysis (CHN).

Dr OUEDRAOGO Noufou has completed his PhD at the age of 34 years from Université de Ouagadougou (Burkina Faso) and Université Claude Bernard Lyon1 (France) and postdoctoral studies from Université Toulouse 3 (UMR152 IDR, France) and Research institute of healh science (IRSS/CNRST-Burkina Faso). He has published more than 15 papers in reputed journals and has been serving as reviewer. He Actually is a researcher at traditional medecine department of IRSS/CNRST.

Pterocarpus erinaceus Poir. (Fabaceae) is used in Burkina Faso folk medicine to treat several diseases, its stem barks are utilized in the treatment of rheumatoid arthritis, tumor, cancer, ulcer and infectious diseases. The aim of the study was to investigate pharmacological and phytochemical activities of extracts from P. erinaceus tem barks. The cytotoxicity of methanol extract from stem bark of this plant against cancer cell lines (Leukemia cell K562 and lung small cells A549), and its inhibition of NF-кB activation in K562 cells and lipoxygenase were studied. Anti-inflammatory activity of methanol extract was evaluated using oil croton at mice. Additionally phytochemical composition including phenolic, tannins, flavonoids and flavonols was determined by using standard methods. At 50 μg/mL, the methanol extract of P. erinaceus inhibited the growth of K562 and A549 cells with inhibition percentage of 46.2±4.0 and 59.4±4.5% respectively. Methanol extract inhibited NF-кB activation at 50 μg/mL (86.5±2.7%), and lipoxygenase activity was significantly inhibited by extract at 100 μg/mL (97.7±0.5%). Methanol extracts inhibited ear edema 85.4% at 500 µg/ear. Extract exhibited an antioxidant capacity like trolox with DPPH method. Pterocarpus erinaceus stem bark showed significant pharmacological properties. These pharmacological effects could be due to the presence of phenolic compounds, tannins, flavonoids and flavonols

Vikrant Chandrakant Sangar has completed graduation in Molecular Biology and Biochemistry from University of Central Lancashire, UK and postgraduation in Medical Oncology from University of Nottingham, UK. He has submitted doctoral thesis on Human Papillmavirus Vacines to Maharahstra University of Health Science, Nashik where he published more than 12 international research aticles on HPV and HPV vaccines. He is the Senor Research Officer/dept.-in charge of Molecular biology dept. of reputed Wadia Hospital, Parel, INDIA. He has published more than 30 papers in reputed journals for like cervical cancer, HPV, HPV vaccines, TB, HIV, stem cells, dengue, nanotechnology, drug develpoment, herbal formulations, CRISPR/Cas, diabetes and foensic science and has been serving as an editorial board member of repute. In the year, 2015 Office for Global Health-University of Sydneyhe invited him as delegate from India to deliver special lecture on HPV vaccines.

High-risk human papillomavirus (HPV) 18 is a main causative agent of cervical intraepithelial neoplasias and cervical cancer. Upon HPV infection, the viral oncoprotein E6 disrupts the host tumor-suppressor protein p53 to promote malignant transformation of normal cervical cells. Current vaccines and therapies targeting HPV18-E6 cannot treat established human papillomavirus (HPV) infection. Therefore, successful HPV eradication would require inactivation of viral oncogene E6. The aim of present study was to achieve targeted knock-out of oncogene E6 from Hela cell lines using clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated9 (Cas9) system. To accomplish this, unique gRNA (KU587439) against HPV18-E6 gene designed by using the Zifit software Version 4.2 and gblock without any 5’ modification cloned into PCR Blunt II TOPO cloning vector. Then KU587439 and vector (1:1) were transfected into 9 x 104 of HeLa cells using lab optimized lipofectamine 3000 range to prevent lipofectamine-related cell toxicity. Cell lysates obtained hereafter used further for Surveyor assay, flow cytometry, RT-PCR and Illumina sequencing. Target specificity of KU587439 was performed by Illumina sequencing. Our obtained results showed that KU587439 gRNA targeting HPV18-E6 remarkably reduced the abilities of proliferation of cervical cancer cells in vitro without producing off-targets. In RT-PCR HPV18-E6 expression reduced by 20,000-fold. This work provided new evidence for application of CRISPR/Cas9 targeting HPV18 E6 as a new treatment strategy which will act as new dawn in cervical and other HPV-associated cancer therapy to cure patients.

Hiren K Kadikar has completed his Master of Pharmacy in Pharmaceutical Analysis from A.R. College of Pharmacy & G.H. Patel Institute of Pharmacy, Anand, Gujarat (India) in 2006. He is Head of Department & Associate Professor in department of Pharmaceutical Analysis in Arihant School of Pharmacy & BRI, Gujarat, India. His area of research is analytical method development & validation. He has 10 years’ experience of teaching & research. He has guided more than 18 M.Pharm students. He has published more than 16 papers in reputed journals.

Accurate, precise, economicalfirstorderderivative spectroscopic method was developed and validated for the estimation of Simvastatin and coenzyme Q10 in synthetic mixture and formulated simvastatin tablet. The wavelengths selected for quantitation were 288.0 nm for Coenzyme Q10 (zero cross for simvastatin) and 236.0 nm for simvastatin (zero cross for Coenzyme Q10). Linearity for detector response was observed in the concentration range of 2-12 μg/ml forsimvastatin with correlation coefficient 0.999. Linearity for detector response was observed in the concentration range of 5-30 μg/ml for coenzyme Q10 with correlation coefficient 0.999. The proposed method was successfully applied for the simultaneous estimation of both drugs in formulated tablet preparation. A reverse phase high performance liquid chromatographic method was developed for the simultaneous estimation of Simvastatin and Coenzyme Q10 in synthetic mixture and formulated tablet. The separation was Achieved by Thermo Hypersil-Keystone (250 mm x 4 mm)5 μm column and Acetonitrile: TetrahydroFuran (80:20 % v/v) as mobile phase, at a flow rate of 1.0 ml/min. Detection was carried out at 254 nm. Retention time of Simvastatin and Coenzyme Q10 was found to be 3.60 and 6.46 min, respectively. The method has been validated for linearity, accuracy and precision. Linearity for Simvastatin and Coenzyme Q10 were in the range of 5-30 μg/ml. The percentage recoveries obtained for Simvastatin and Coenzyme Q10 were found in tablet. Developed method was found to be accurate, precise, selective and rapid for simultaneous estimation of Simvastatin and Coenzyme Q10 in formulated simvastatin tablets and synthetic mixture. Bothsimvastatin andcoenzyme Q10 were found to bedirectly Compressible and hence direct compression method was chosen for the formulation of tablet dosage form with the MCC as directly compressible diluents, Magnesium stearate a a glidant and Talc as a lubricant and glidant. The dose of simvastatin and coenzyme Q10 was in the tablet 20 mg and 40 mg respectively.

Upendra L Patel has completed his PhD from Sardar Patel University, Anand, Gujarat (India) in 2010. He is Head of Department & Associate Professor in department of Pharmaceutics & Pharmaceutical Technology in Arihant School of Pharmacy & BRI, Gujarat, India. His area of research is formulation and evaluation of controlled drug delivery formulations. He has guided more than 25 MPharm students. He has published more than 40 papers in reputed journals and one book of Dispensing Pharmacy & Drug Store Management. He is life time member of Gujarat Pharmacy Teacher Associations.

To formulate and evaluate a press coated pulsatile release tablets of prednisolone using an admixture of hydrophilic polymer, i.e., low substituted hydroxy propyl cellulose (L-HPC) and hydrophobic polymer, i.e., ethyl cellulose (Ethocel 10 cps) in order to achieve a pre-determined lag time for chronotherapy of rheumatoid arthritis. The press coated pulsatile tablets containing prednisolone in the inner core were prepared by compression coating with L-HPC and Ethocel 10 cps as the outer layer in different ratios. The effect of polymer ratio and weight gain of the outer layer on lag time of drug release was investigated using 32 full factorial design. The parameters determined were tablet hardness, friability, drug content, lag time, in vitro dissolution. The release profile of the press coated tablet exhibited a distinct lag time before burst release of prednisolone. Lag time was dependent on the ratio of L-HPC/Ethocel 10 cps and weight gain in outer shell. The lag time was from 1 to 10 hr and could be modulated as it decreased as the amount of L-HPC in the outer layer increased. A surface plots are also presented to graphically represent the effect of independent variables on the lag time. The validity of generated mathematical model was tested by preparing checkpoint formulation.Formulation PCPT7 with L-HPC/Ethocel 10 cps (10:90) and weight gain 300 mg showing predetermined lag time of 5 hr prior to burst release of the drug from the press coated tablet was taken as the optimized formulation.